Search results
Results from the WOW.Com Content Network
This is a list of investigational anxiolytics, or anxiolytics that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. This list was last comprehensively updated in June 2017.
Pitressin among others, is a medication most commonly used in the treatment of frequent urination, increased thirst, and dehydration such as that resulting from diabetes insipidus, which causes increased and diluted urine. [2] [3] It is used to treat abdominal distension following some surgeries, and in stomach roentgenography. [3]
Nitrazepam, sold under the brand name Mogadon among others, [2] [3] is a hypnotic drug of the benzodiazepine class used for short-term relief from severe, disabling anxiety and insomnia. [4] It also has sedative (calming) properties, [ 5 ] as well as amnestic (inducing forgetfulness), anticonvulsant , and skeletal muscle relaxant effects.
In Australia, each tablet contains 2.5, 5, or 10 mg of perindopril arginine. Perindopril is also available under the trade name Coversyl Plus, containing 5 mg of perindopril arginine combined with 1.25 mg indapamide and Coversyl Plus LD , containing 2.5 mg of perindopril arginine combined with 0.625 mg indapamide.
Download as PDF; Printable version; ... International Drug Names: ATC code: ... is a mixture of two amino acids, 50% arginine and 50% glutamic acid, used in liver ...
Tiagabine is approved by U.S. Food and Drug Administration (FDA) as an adjunctive treatment for partial seizures in individuals of age 12 and up. It may also be prescribed off-label by physicians to treat anxiety disorders and panic disorder as well as neuropathic pain (including fibromyalgia).
[1] [2] Chemically, it is a methyl derivative of the amino acid arginine. It is used as a biochemical tool in the study of physiological role of nitric oxide . The inhibiting effect of N -methylarginine on vasodilation is lower in hypertensive patients than in normal subjects, indicating endothelial dysfunction . [ 3 ]
Due to its long elimination half-life, triazoledione is the major metabolite and predominates in the circulation during nefazodone treatment, with plasma levels that are 4 to 10 times higher than those of nefazodone itself. [2] [35] Conversely, hydroxynefazodone levels are about 40% of those of nefazodone at steady state. [2]